Tiziana CEO Elrifi buys more shares on two dates in August 2026

Tiziana Life Sciences Ltd disclosed in a pair of Form 6-K filings that its Chief Executive Officer, Ivor Elrifi, made two separate open-market purchases of the company's common shares in August 2026.

In the first filing, dated August 4, 2026, the company said Elrifi increased his holdings with the purchase of 667,000 common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,472,261 common shares.¹

Two days later, in a filing dated August 6, 2026, Tiziana reported an additional purchase. According to that release, Elrifi bought 321,423 of the company's shares on NASDAQ at $1.00 each, bringing his total holding to 4,793,684 common shares.²

Both filings describe Tiziana as a biotechnology company whose lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The company stated that foralumab has been shown to stimulate T regulatory cells when dosed intranasally.²

On the clinical front, the filings noted that 14 patients with Non-Active Secondary Progressive Multiple Sclerosis have been dosed in an open-label intermediate sized Expanded Access Program, listed as NCT06802328, with all patients showing either improvement or stability of disease within 6 months.² Separately, the company said foralumab is being evaluated in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis, registered as NCT06292923.²

The filings were signed by Chief Financial Officer Keeren Shah on the respective dates and furnished as exhibits, not filed under Section 18 of the Securities Exchange Act of 1934.